vs

Side-by-side financial comparison of Phathom Pharmaceuticals, Inc. (PHAT) and Vera Bradley, Inc. (VRA). Click either name above to swap in a different company.

Vera Bradley, Inc. is the larger business by last-quarter revenue ($62.3M vs $57.6M, roughly 1.1× Phathom Pharmaceuticals, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs -22.7%). Vera Bradley, Inc. produced more free cash flow last quarter ($-4.5M vs $-167.0M).

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.

Vera Bradley Sales, LLC is an American luggage and handbag design company, founded by Barbara Bradley Baekgaard and Patricia R. Miller in 1982. As of 2019, its home office is in Fort Wayne, Indiana. The company was named after Baekgaard's mother. Its original luxury cotton bag product lines have expanded to include fashion and home accessories, office supplies, and patterned gifts. Many items have distinctive florals, paisleys, or geometric prints with complementary linings, as well as elonga...

PHAT vs VRA — Head-to-Head

Bigger by revenue
VRA
VRA
1.1× larger
VRA
$62.3M
$57.6M
PHAT
Growing faster (revenue YoY)
PHAT
PHAT
+116.9% gap
PHAT
94.1%
-22.7%
VRA
More free cash flow
VRA
VRA
$162.5M more FCF
VRA
$-4.5M
$-167.0M
PHAT

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
PHAT
PHAT
VRA
VRA
Revenue
$57.6M
$62.3M
Net Profit
$-12.4M
Gross Margin
86.7%
42.1%
Operating Margin
-19.6%
Net Margin
-19.9%
Revenue YoY
94.1%
-22.7%
Net Profit YoY
71.6%
3.4%
EPS (diluted)
$-0.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PHAT
PHAT
VRA
VRA
Q4 25
$57.6M
$62.3M
Q3 25
$49.5M
$70.9M
Q2 25
$39.5M
$51.7M
Q1 25
$28.5M
$100.0M
Q4 24
$29.7M
$70.5M
Q3 24
$16.4M
$94.0M
Q2 24
$7.3M
$67.9M
Q1 24
$46.2M
Net Profit
PHAT
PHAT
VRA
VRA
Q4 25
$-12.4M
Q3 25
$-30.0M
$-4.7M
Q2 25
$-75.8M
$-33.5M
Q1 25
$-94.3M
$-47.0M
Q4 24
$-12.8M
Q3 24
$-85.6M
$5.7M
Q2 24
$-91.4M
$-8.1M
Q1 24
$-1.9M
Gross Margin
PHAT
PHAT
VRA
VRA
Q4 25
86.7%
42.1%
Q3 25
87.5%
50.1%
Q2 25
87.2%
44.1%
Q1 25
86.9%
45.0%
Q4 24
87.1%
54.5%
Q3 24
85.6%
49.7%
Q2 24
81.2%
50.1%
Q1 24
37.2%
Operating Margin
PHAT
PHAT
VRA
VRA
Q4 25
-19.6%
Q3 25
-30.8%
-6.5%
Q2 25
-151.7%
-34.6%
Q1 25
-276.5%
-23.3%
Q4 24
-11.6%
Q3 24
-433.0%
2.5%
Q2 24
-1055.4%
-15.6%
Q1 24
-3.6%
Net Margin
PHAT
PHAT
VRA
VRA
Q4 25
-19.9%
Q3 25
-60.5%
-6.6%
Q2 25
-191.9%
-64.8%
Q1 25
-330.7%
-47.0%
Q4 24
-18.2%
Q3 24
-523.3%
6.1%
Q2 24
-1248.6%
-12.0%
Q1 24
-4.0%
EPS (diluted)
PHAT
PHAT
VRA
VRA
Q4 25
$-0.44
Q3 25
$-0.41
$-0.17
Q2 25
$-1.05
$-1.20
Q1 25
$-1.31
$-1.62
Q4 24
$-0.46
Q3 24
$-1.32
$0.19
Q2 24
$-1.56
$-0.26
Q1 24
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PHAT
PHAT
VRA
VRA
Cash + ST InvestmentsLiquidity on hand
$130.0M
$10.7M
Total DebtLower is stronger
$209.1M
$10.0M
Stockholders' EquityBook value
$-438.2M
$128.1M
Total Assets
$259.1M
$243.7M
Debt / EquityLower = less leverage
0.08×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PHAT
PHAT
VRA
VRA
Q4 25
$130.0M
$10.7M
Q3 25
$135.2M
$15.2M
Q2 25
$149.6M
$11.3M
Q1 25
$212.3M
$30.4M
Q4 24
$297.3M
$13.7M
Q3 24
$334.7M
$44.1M
Q2 24
$276.2M
$55.2M
Q1 24
$77.3M
Total Debt
PHAT
PHAT
VRA
VRA
Q4 25
$209.1M
$10.0M
Q3 25
$207.1M
$10.0M
Q2 25
$205.1M
Q1 25
$203.2M
$0
Q4 24
$201.4M
Q3 24
$175.7M
Q2 24
$174.4M
Q1 24
Stockholders' Equity
PHAT
PHAT
VRA
VRA
Q4 25
$-438.2M
$128.1M
Q3 25
$-422.5M
$140.5M
Q2 25
$-405.8M
$146.0M
Q1 25
$-338.4M
$179.0M
Q4 24
$-253.6M
$225.2M
Q3 24
$-187.1M
$242.5M
Q2 24
$-233.8M
$245.9M
Q1 24
$259.9M
Total Assets
PHAT
PHAT
VRA
VRA
Q4 25
$259.1M
$243.7M
Q3 25
$240.3M
$266.2M
Q2 25
$250.2M
$267.9M
Q1 25
$294.2M
$306.7M
Q4 24
$378.3M
$359.0M
Q3 24
$387.0M
$379.2M
Q2 24
$319.4M
$368.7M
Q1 24
$380.8M
Debt / Equity
PHAT
PHAT
VRA
VRA
Q4 25
0.08×
Q3 25
0.07×
Q2 25
Q1 25
0.00×
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PHAT
PHAT
VRA
VRA
Operating Cash FlowLast quarter
$-166.8M
$-4.0M
Free Cash FlowOCF − Capex
$-167.0M
$-4.5M
FCF MarginFCF / Revenue
-290.0%
-7.2%
Capex IntensityCapex / Revenue
0.4%
0.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-328.9M
$-13.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PHAT
PHAT
VRA
VRA
Q4 25
$-166.8M
$-4.0M
Q3 25
$-14.1M
$-5.4M
Q2 25
$-62.7M
$-17.9M
Q1 25
$-84.9M
$21.7M
Q4 24
$-266.8M
$-22.6M
Q3 24
$-63.6M
$1.4M
Q2 24
$-70.7M
$-14.5M
Q1 24
$26.9M
Free Cash Flow
PHAT
PHAT
VRA
VRA
Q4 25
$-167.0M
$-4.5M
Q3 25
$-14.1M
$-6.1M
Q2 25
$-62.8M
$-19.8M
Q1 25
$-84.9M
$17.3M
Q4 24
$-266.9M
$-25.0M
Q3 24
$-63.6M
$-1.4M
Q2 24
$-70.8M
$-15.4M
Q1 24
$25.7M
FCF Margin
PHAT
PHAT
VRA
VRA
Q4 25
-290.0%
-7.2%
Q3 25
-28.6%
-8.7%
Q2 25
-159.0%
-38.3%
Q1 25
-297.9%
17.3%
Q4 24
-899.8%
-35.5%
Q3 24
-389.0%
-1.5%
Q2 24
-966.2%
-22.7%
Q1 24
55.7%
Capex Intensity
PHAT
PHAT
VRA
VRA
Q4 25
0.4%
0.7%
Q3 25
0.1%
1.0%
Q2 25
0.2%
3.6%
Q1 25
0.1%
4.3%
Q4 24
0.5%
3.4%
Q3 24
0.3%
3.0%
Q2 24
0.6%
1.3%
Q1 24
2.6%
Cash Conversion
PHAT
PHAT
VRA
VRA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.25×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PHAT
PHAT

Segment breakdown not available.

VRA
VRA

Bags$23.9M38%
Indirect$12.6M20%
Transferred At Point In Time$12.2M20%
Accessories$7.2M12%
Home$3.5M6%
Apparel Footwear$1.8M3%
Other Products$1.5M2%

Related Comparisons